Posts

CureApp SC, Digital Therapeutic for Nicotine Addiction: Introducing a New Form of App-based Prescription Treatment

Image
  CureApp SC, Digital  Therapeutic for  Nicotine Addiction:  Introducing a New Form of App-based  Prescription  Treatment  -  The Firs t Digital Therapeutic  to Be Covered by Japan’s Public Healthcare Insurance System CureApp, Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Kohta Satake) has announced that CureApp SC Nicotine Addiction Treatment App and CO Checker (hereafter, CureApp SC) – a treatment app(digital therapeutic) targeting nicotine addiction – is now covered by Japan’s public healthcare insurance system as of December 1, 2020, following a period of clinical trials and regulatory approval. This marks the first case of a digital therapeutics application being covered by the insurance, as well as the first time that a digital therapeutic in the field of smoking cessation treatments has been covered by a country’s national health insurance system in the world. Patients diagnosed with nicotine addiction at a medical institution are eligible for insurance reimbursement when a doctor pr

【Publication information】 Nicotine Addiction Treatment App With CO Checker Receives Regulatory Approval - CureApp, Inc.

Image
We are pleased to inform you that the article has been published with the approval of our Nicotine Addiction Treatment App With CO Checker.   Bio Space Asia’s First Prescription “Digital Therapeutic” Approved in Japan; Nicotine Addiction Treatment App With CO Checker Receives Regulatory Approval - CureApp, Inc.   https://www.biospace.com/article/releases/asia-s-first-prescription-digital-therapeutic-approved-in-japan-nicotine-addiction-treatment-app-with-co-checker-receives-regulatory-approval-cureapp-inc-/?s=85&utm_source=dlvr.it&utm_medium=twitter

Asia’s First Prescription “Digital Therapeutic” Approved in Japan ; Nicotine Addiction Treatment App with CO Checker Receives Regulatory Approval

Image
  Entering a New Age Where Innovative Treatments Are Provided With an App Asia’s First Prescription “Digital Therapeutic” Approved in Japan Nicotine Addiction Treatment App with CO Checker Receives Regulatory Approval The World’s First App-based Nicotine Addiction Treatment     CureApp, Inc. (Headquarter: Chuo-ku, Tokyo; CEO: Kohta Satake) received regulatory authorization for the manufacturing and sale of Asia’s first therapeutics app, the “CureApp SC Nicotine Addiction Treatment App and CO Checker” (hereafter, CureApp SC), from the Ministry of Health, Labour and Welfare (MHLW) on August 21st, 2020. The Company is currently proceeding with plans to receive insurance reimbursement and release CureApp SC in FY2020. CureApp SC  CureApp SC is a prescription medical device designed to aid patients who are receiving outpatient smoking cessation treatment. The device supports patients in their attempt to quit smoking in a home setting.  The product consists of three components - a patient ap

CureApp Named to the 2020 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups

Image
CureApp Named to the 2020 CB Insights Digital Health 150 -- List of Most Innovative Digital Health Startups  CureApp recognized for achievements in develop evidence-based medical programs, “Digital Therapeutics (DTx),” for patients who suffer from conditions that conventional treatment methods with drugs or devices were not effective   NEW YORK, August 13, 2020 -- CB Insights today named CureApp to its second annual Digital Health 150 ranking, which showcases the 150 most promising private digital health companies in the world. The 2020 Digital Health 150 cohort highlights startups that are reimagining the lines of the traditional healthcare experience across 12 categories, from Virtual Care Delivery and Clinical Trials, to Drug Discovery and Specialty Care. Countries represented this year include Canada, China, Israel, France, the United Kingdom, and the United States, among others. “This year’s Digital Health 150 is our most global ever, covering the best private healthcare compa

【Publication information】"Digital Therapeutics will Become a Major Treatment Option in the Future: Kohta Satake, CEO of CureApp."

Image
We are pleased to inform you that our article has been published on Smart Industry News titled "Digital Therapeutics will Become a Major Treatment Option in the Future: Kohta Satake, CEO of CureApp." https://www.smartindustrynews.com/sin-article/digital-therapeutics-will-become-a-major-treatment-option-in-the-future-kohta-satake-ceo-of-cureapp/

CureApp Awarded as Technology Pioneer by World Economic Forum

Image
The World Economic Forum announced its selection of 100 of the most promising Technology Pioneers of 2020, who are shaping industries from agriculture to healthcare while also working on sustainability issues and much more. Many Technology Pioneers are also using their tech to support COVID-19 responses around the world. CureApp, which develops evidence-based software medical devices (DTx: Digital Therapeutics) as a new treatment regimen, made it to the selection for its contributions in the field of health care and medicine. The full list of recognized Technology Pioneers can be viewed here. 16 June, 2020 – CureApp, a Tokyo-based company that develops “Digital Therapeutics (DTx),” was selected among hundreds of candidates as one of the World Economic Forum’s “Technology Pioneers”. CureApp, founded by Kohta Satake MD/MPH/MBA and Shin Suzuki MD, is a pioneering digital therapeutics company that aims to re-evolve the future of "therapeutics" with software via

The First Phase 3 Clinical Trials of "Digital Therapeutics" for Hypertension Begin in Japan

Image
Jichi Medical University and CureApp, Inc. The First Phase 3 Clinical Trials of "Digital Therapeutics" for Hypertension Begin in Japan Verifying the standalone therapeutic efficacy of the app in patients untreated with anti hypertensive drugs  A new treatment for hypertension, the disease with the highest number of patients in Japan, incurring medical costs in the order of $17 billion USD  CureApp, Inc. (Head Office, Chuo-ku, Tokyo; President and CEO, Kohta Satake, M.D.), developer of software as a medical device “Digital Therapeutics” mobile applications, has launched a Phase 3 multicenter, randomized comparative study (clinical trial) of "Digital Therapeutics“ for hypertension in Japan with various partners including Professor Kazuomi Kario, M.D., Ph.D., the Division of Cardiovascular Medicine, the Department of Medicine, and Jichi Medical University School of Medicine.  This study will evaluate the efficacy and safety of "Digital Therapeutics" in p